Loading...
Docoh

Tenax Therapeutics (TENX)

Employees
Data from SEC filings
Employee count
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

Tenax Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 10, 2021 (the “Annual Meeting”). The stockholders considered the four proposals described below, each of which is described in more detail in the Company’s definitive proxy statement dated April 30, 2021 (the “Proxy Statement”). As of April 13, 2021, the record date for the Annual Meeting, there were 14,969,312 shares of common stock issued, outstanding and entitled to vote. At the Annual Meeting, 12,427,891 shares of common stock were represented in person or by proxy, constituting a quorum. The final number of votes cast for and against, as well as the number of abstentions and broker non-votes, with respect to each proposal are set forth below.

Proposal 1: To elect the nine (9) director nominees described in the Proxy Statement to the Company’s Board of Directors to serve until the sooner of the 2022 Annual Meeting of the Company’s Stockholders or the election and qualification of their successors. The votes were cast as follows: